Antibody therapies take the spotlight as ‘Plan B’ to treat coronavirus

After disappointing results from some repurposed drugs like the cheap generic HCQ, investors may be looking at therapeutic antibodies.

An experimental antibody therapy to combat Covid-19 from Regeneron Pharmaceuticals Inc. got a shot of confidence from the U.S. government on Tuesday with a $450 million contract to start amping up production.

With Regeneron and Eli Lilly & Co. expected to have results in the current quarter, the latest funding may signal a new plan of attack for President Donald Trump.

Lilly, working with closely held AbCellera Biologics Inc., and Regeneron are **leading the development of so-called “neutralizing” antibodies that are tailored to mimic immune responses to the virus. **Other companies racing to come up with similar treatments include AstraZeneca Plc and Vir Biotechnology Inc. in partnership with GlaxoSmithKline Plc

This gives us an opportunity to take position in great companies like AstraZeneca and GlaxoSmithKline plc.
#way2wealth

Details available at https://theprint.in/science/antibody-therapies-take-the-spotlight-as-plan-b-to-treat-coronavirus/456599/

#Covid